Skip to content

AstraZeneca Studies Listing of New Vaccines Division

  • Pharma giant said it was creating new vaccines unit last month
  • Top management discusses range of options for business
Photographer: Andre Malerba/Bloomberg
Updated on

AstraZeneca Plc has been studying options including a potential listing of its newly-created vaccines division as it seeks ways to boost returns for investors, people with knowledge of the matter said. 

The U.K. pharmaceutical giant is in the early stages of considering the best positioning for the vaccine unit, the people said, asking not to be identified because the information is private. Top management have discussed a range of possibilities with advisers including a flotation of the business, the people said.